Novo Nordisk Pitches DJ Khaled and Liver Data Against a Cautious Street
Published on 11/13/2026 at 20:11 | Editorial boerse-global.de
Novo Nordisk has paired a celebrity marketing push for Wegovy with fresh clinical evidence, unveiling a partnership with DJ Khaled and a new analysis from the ESSENCE trial as it tries to convert attention into prescriptions. The stock rose 2.2% on the day the campaign was announced.
The collaboration leans on the producer's own experience with weight management, with DJ Khaled expected to share insights into his daily routine and his use of Wegovy. Whether that visibility translates into extra demand is the open question — the commercial payoff depends on Novo turning interest into revenue.
That bar is already set high. On 4 November the company raised its full-year guidance on stronger expectations for GLP-1 sales, and the outlook has now been lifted three times in total.
Guidance Leaves Room in Both Directions
For 2026, Novo projects adjusted sales growth of between -2% and +2% at constant exchange rates, with adjusted operating profit guided to the same range. The forecast therefore spans a modest decline as well as a modest advance.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The third quarter of 2026 offers a positive starting point. Net sales came in at DKK 79,195 million, up 4% at constant currencies and ahead of analyst estimates. Adjusted operating profit climbed 27% at constant exchange rates to DKK 31,720 million.
The oral form of Wegovy supplied much of the momentum: quarterly sales of the tablet reached DKK 5.39 billion, a 53% jump on the prior quarter. BMO Capital Markets, which links its improved expectations to that strength, estimates US sales ran 17% above consensus.
Two Analysts, One Verdict
Berenberg has reaffirmed its Hold rating on the shares ahead of the planned launch of CagriSema, and BMO Capital Markets likewise pairs its brighter expectations with a neutral stance. Both houses want further progress before turning more positive on the equity.
The Wegovy pill launched in the US in January. Novo intends to roll it out in more than 20 countries by mid-2027, contingent on sufficient manufacturing capacity and the necessary approvals — a test of whether the tablet's strong run can travel beyond its first market.
Further out, the growth story faces mounting pressure. Core Novo Nordisk products confront a phased wave of patent expirations from 2031, with Lilly among the competitors.
Liver Data Broaden the Case for Semaglutide
Supporting the bull case, Novo on Sunday presented a post-hoc analysis of the ESSENCE study covering adults with MASH and liver scarring who had a BMI below 27 kg/m². At a 2.4 mg dose of semaglutide, patients showed improvements versus placebo in liver injury, fibrosis and disease activity.
Those findings widen the scientific footing for Wegovy. On 6 November the company had already released results from the PLATINUM-Truveta and RHODIUM-2 care studies, in which Wegovy treatment in adults with MASH was associated with lower liver enzyme levels as well as reduced weight and blood sugar.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The caveats are built in. The ESSENCE readout was a retrospective analysis of a specific patient group, and the care studies describe associations observed under treatment conditions rather than controlled trial outcomes. How far these results hold up for the broader medical and commercial picture is what matters for a more optimistic view.
The Year-End Report Is the Next Test
If Novo delivers operationally on its raised GLP-1 expectations, a better outcome within the guidance range looks plausible; growth at the top end would give the marketing and medical narrative a financial foundation. Should sales drift toward the bottom of the range, the more cautious reading would gain support.
The next hard date is 3 February 2027, when Novo Nordisk publishes its financial statements and annual report for 2026 — the moment investors can see where the company actually landed inside its lifted forecast.
Ad
Novo Nordisk Stock: New Analysis - 13 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
